Targeted therapies in breast cancer such as trastuzumab, cetuximab, and lapatinib, which block the Her-1/2 pathway, can cause G1 cell cycle arrest and also highly increase TXNIP expression [174]. Here, EGFR is linked to breast carcinoma.